People · Operator
Named in public records as an officer, director or promoter · active 2009–2013 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Alimera Sciences Inc | — | Pharmaceuticals | Series C | $173.8M | $1.1B | 2009 |
| Mevion Medical Systems, Inc. | — | Biotechnology | Series C | $95.3M | $2.4B | 2011 |
| Anacor Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $19.4M | $83.6M | 2010 |
| QUATRX PHARMACEUTICALS Co | — | Pharmaceuticals | Series A | $14.0M | $434.4M | 2009 |
Anders Hove at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Anders Hove on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Patrick Heron | 1 | 11 |
| David Perry | 1 | 11 |
| Brian Halak | 1 | 10 |
| Mark Leschly | 1 | 9 |
| Robert Wilson | 1 | 7 |
| Myles Greenberg | 1 | 6 |
| Paul Klingenstein | 1 | 6 |
| Chris Ehrlich | 1 | 6 |
| Mitchell Bloom | 1 | 6 |
| Brian K. Halak | 1 | 5 |
| Kenneth Gall | 1 | 5 |
| Mark Brooks | 1 | 5 |
| William Rieflin | 1 | 4 |
| Jay Moorin | 1 | 4 |
| Mary T. Szela | 1 | 4 |
| Richard Markham | 1 | 3 |
| Marc Buntaine | 1 | 3 |
| Geoffrey Parker | 1 | 3 |
| Peter J. Pizzo III | 1 | 3 |
| Paul Berns | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.